93 related articles for article (PubMed ID: 20555430)
21. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.
De Leo V; la Marca A; Morgante G; Lanzetta D; Setacci C; Petraglia F
Am J Obstet Gynecol; 2001 Feb; 184(3):350-3. PubMed ID: 11228485
[TBL] [Abstract][Full Text] [Related]
22. Raloxifene: bone and cardiovascular effects.
Francucci CM; Romagni P; Boscaro M
J Endocrinol Invest; 2005; 28(10 Suppl):85-9. PubMed ID: 16550730
[TBL] [Abstract][Full Text] [Related]
23. Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate.
Palacios S; Farias ML; Luebbert H; Gomez G; Yabur JA; Quail DC; Turbi C; Kayath MJ; Almeida MJ; Mönnig E; Nickelsen T
Am J Obstet Gynecol; 2004 Jul; 191(1):121-31. PubMed ID: 15295352
[TBL] [Abstract][Full Text] [Related]
24. [Effects of raloxifene on endothelial function and hemostasis in women with ischemic heart disease].
Roqué M; Sitges M; Sala J; Delgado V; Morales M; Marrugat J; Vila J; Subirana I; Tàssies D; Reverter JC; Castro M; Duran M
Rev Esp Cardiol; 2011 Jul; 64(7):572-8. PubMed ID: 21601973
[TBL] [Abstract][Full Text] [Related]
25. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
[TBL] [Abstract][Full Text] [Related]
26. Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women.
Vehkavaara S; Silveira A; Hakala-Ala-Pietilä T; Virkamäki A; Hovatta O; Hamsten A; Taskinen MR; Yki-Järvinen H
Thromb Haemost; 2001 Apr; 85(4):619-25. PubMed ID: 11341495
[TBL] [Abstract][Full Text] [Related]
27. Effects of raloxifene on serum macrophage colony-stimulating factor and interleukin-18 levels in postmenopausal women younger than 60 years.
Oztas E; Kurtay G
Menopause; 2010; 17(6):1188-93. PubMed ID: 20613670
[TBL] [Abstract][Full Text] [Related]
28. Comparative analysis of oestrogen and raloxifene effects on the phospholipid composition of high density lipoproteins in healthy postmenopausal women.
Piperi C; Kalofoutis C; Papapanagiotou A; Skenderi C; Kalofoutis A
J Obstet Gynaecol; 2004 Jan; 24(1):52-7. PubMed ID: 14675982
[TBL] [Abstract][Full Text] [Related]
29. A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.
Reid IR; Eastell R; Fogelman I; Adachi JD; Rosen A; Netelenbos C; Watts NB; Seeman E; Ciaccia AV; Draper MW
Arch Intern Med; 2004 Apr; 164(8):871-9. PubMed ID: 15111373
[TBL] [Abstract][Full Text] [Related]
30. [Effects of raloxifene combined with conjugated equine estrogen on prothrombotic state in ovariectomized rats].
Gao H; Xi S; Xu L
Zhonghua Fu Chan Ke Za Zhi; 2013 Dec; 48(12):935-8. PubMed ID: 24495689
[TBL] [Abstract][Full Text] [Related]
31. Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal women.
Vogelvang TE; Mijatovic V; Kenemans P; Schalkwijk CG; van der Mooren MJ
Am J Cardiol; 2004 Nov; 94(9):1205-8. PubMed ID: 15518626
[TBL] [Abstract][Full Text] [Related]
32. Effect of long-term treatment with raloxifene on mammary density in postmenopausal women.
Lasco A; Gaudio A; Morini E; Morabito N; Nicita-Mauro C; Catalano A; Denuzzo G; Sansotta C; Xourafa A; Macrì I; Frisina N
Menopause; 2006; 13(5):787-92. PubMed ID: 16912660
[TBL] [Abstract][Full Text] [Related]
33. Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids.
Oztas E; Kurtay G
Arch Gynecol Obstet; 2011 Jan; 283(1):71-7. PubMed ID: 20012308
[TBL] [Abstract][Full Text] [Related]
34. Role of raloxifene on platelet metabolism and plasma lipids.
Nanetti L; Camilletti A; Francucci CM; Vignini A; Raffaelli F; Mazzanti L; Boscaro M
Eur J Clin Invest; 2008 Feb; 38(2):117-25. PubMed ID: 18226045
[TBL] [Abstract][Full Text] [Related]
35. [Effects of raloxifene on bone biomarkers in postmenopausal women on maintenance haemodialysis].
Matsuo K; Fujinaga M; Tsuchiya K; Nakamoto M; Yasunaga C
Clin Calcium; 2005 Sep; 15 Suppl 1():92-6; discussion 96-7. PubMed ID: 16272639
[TBL] [Abstract][Full Text] [Related]
36. The hemorheological effects of raloxifene in postmenopausal women with osteoporosis. Results of a 3-year placebo-controlled clinical trial.
Shand B; Gilchrist N; Blackwell T; March R
Clin Hemorheol Microcirc; 2002; 26(4):249-55. PubMed ID: 12122230
[TBL] [Abstract][Full Text] [Related]
37. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
[TBL] [Abstract][Full Text] [Related]
38. [Selective estrogen-receptor modulators (SERM's) in postmenopausal women].
Hart W; Netelenbos JC
Ned Tijdschr Geneeskd; 1999 Aug; 143(35):1771-6. PubMed ID: 10494328
[TBL] [Abstract][Full Text] [Related]
39. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
Cosman F; Baz-Hecht M; Cushman M; Vardy MD; Cruz JD; Nieves JW; Zion M; Lindsay R
Thromb Res; 2005; 116(1):1-13. PubMed ID: 15850603
[TBL] [Abstract][Full Text] [Related]
40. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
